<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NORPACE- disopyramide phosphate capsule, gelatin coated </strong><br>Carilion Materials Management<br></p></div>
<h1>Norpace disopyramide phosphate capsules Norpace CR disopyramide phosphate extended-release capsules
        <span class="Sup">®</span><br><br><br><span class="Sup">®</span><br><br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Norpace (disopyramide phosphate) is an antiarrhythmic drug available for oral administration in immediate-release and controlled-release capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. The base content of the phosphate salt is 77.6%. The structural formula of Norpace is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f5e0c230-db38-4476-8357-9a227ccff1bc&amp;name=norpace-01.jpg"></div>
<p>Norpace is freely soluble in water, and the free base (pKa 10.4) has an aqueous solubility of 1 mg/ml. The chloroform:water partition coefficient of the base is 3.1 at pH 7.2.</p>
<p>Norpace is a racemic mixture of and isomers. This drug is not chemically related to other antiarrhythmic drugs.
                            <span class="Italics">d-</span><span class="Italics">l-</span></p>
<p>Norpace CR (controlled-release) capsules are designed to afford a gradual and consistent release of disopyramide. Thus, for maintenance therapy, Norpace CR provides the benefit of less-frequent dosing (every 12 hours) as compared with the every-6-hour dosage schedule of immediate-release Norpace capsules.</p>
<p>Inactive ingredients of Norpace include corn starch, edible ink, FD&amp;C Red No. 3, FD&amp;C Yellow No. 6, gelatin, lactose, talc, and titanium dioxide; the 150-mg capsule also contains FD&amp;C Blue No. 1.</p>
<p>Inactive ingredients of Norpace CR include corn starch, D&amp;C Yellow No. 10, edible ink, ethylcellulose, FD&amp;C Blue No. 1, gelatin, shellac, sucrose, talc, and titanium dioxide; the 150-mg capsule also contains FD&amp;C Red No. 3 and FD&amp;C Yellow No. 6.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-2.1"></a><p></p>
<h2>Mechanisms of Action</h2>
<p class="First">Norpace (disopyramide phosphate) is a Type 1 antiarrhythmic drug (i.e., similar to procainamide and quinidine). Norpace decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and increases the action potential duration of normal cardiac cells, decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and has no effect on alpha- or beta-adrenergic receptors.
                                    <span class="Italics">In animal studies</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>Electrophysiology</h2>
<p class="First">In man, Norpace at therapeutic plasma levels shortens the sinus node recovery time, lengthens the effective refractory period of the atrium, and has a minimal effect on the effective refractory period of the AV node. Little effect has been shown on AV-nodal and His-Purkinje conduction times or QRS duration. However, prolongation of conduction in accessory pathways occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2>Hemodynamics</h2>
<p class="First">At recommended oral doses, Norpace rarely produces significant alterations of blood pressure in patients without <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (see ). With intravenous Norpace, either increases in systolic/diastolic or decreases in systolic blood pressure have been reported, depending on the infusion rate and the patient population. Intravenous Norpace may cause cardiac <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> with an approximate mean 10% reduction of <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, which is more pronounced in patients with cardiac dysfunction.
                                    <span class="Italics"><a href="#Warn">Warnings</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4"></a><p></p>
<h2>Anticholinergic Activity</h2>
<p class="First">The in vitro anticholinergic activity of Norpace is approximately 0.06% that of atropine; however, the usual dose for Norpace is 150 mg every 6 hours and for Norpace CR 300 mg every 12 hours, compared to 0.4 to 0.6 mg for atropine (see and for anticholinergic side effects).
                                    <span class="Italics"><a href="#Warn">Warnings</a></span><span class="Italics"><a href="#Adv-React">Adverse Reactions</a></span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-2.5"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Following oral administration of immediate-release Norpace, disopyramide phosphate is rapidly and almost completely absorbed, and peak plasma levels are usually attained within 2 hours. The usual therapeutic plasma levels of disopyramide base are 2 to 4 mcg/ml, and at these concentrations protein binding varies from 50% to 65%. Because of concentration-dependent protein binding, it is difficult to predict the concentration of the free drug when total drug is measured.</p>
<p>The mean plasma half-life of disopyramide in healthy humans is 6.7 hours (range of 4 to 10 hours). In six patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance less than 40 ml/min), disopyramide half-life values were 8 to 18 hours.</p>
<p>After the oral administration of 200 mg of disopyramide to 10 cardiac patients with borderline to moderate <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, the time to peak serum concentration of 2.3 ± 1.5 hours (mean ± SD) was increased, and the mean peak serum concentration of 4.8 ± 1.6 mcg/ml was higher than in healthy volunteers. After intravenous administration in these same patients, the mean elimination half-life was 9.7 ± 4.2 hours (range in healthy volunteers of 4.4 to 7.8 hours). In a second study of the oral administration of disopyramide to 7 patients with heart disease, including <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>, the mean plasma half-life was slightly prolonged to 7.8 ± 1.9 hours (range of 5 to 9.5 hours).</p>
<p>In healthy men, about 50% of a given dose of disopyramide is excreted in the urine as the unchanged drug, about 20% as the mono-N-dealkylated metabolite, and 10% as the other metabolites. The plasma concentration of the major metabolite is approximately one tenth that of disopyramide. Altering the urinary pH in man does not affect the plasma half-life of disopyramide.</p>
<p>In a crossover study in healthy subjects, the bio-availability of disopyramide from Norpace CR capsules was similar to that from the immediate-release capsules. With a single 300-mg oral dose, peak disopyramide plasma concentrations of 3.23 ± 0.75 mcg/ml (mean ± SD) at 2.5 ± 2.3 hours were obtained with two 150-mg immediate-release capsules and 2.22 ± 0.47 mcg/ml at 4.9 ± 1.4 hours with two 150-mg Norpace CR capsules. The elimination half-life of disopyramide was 8.31 ± 1.83 hours with the immediate-release capsules and 11.65 ± 4.72 hours with Norpace CR capsules. The amount of disopyramide and mono-N-dealkylated metabolite excreted in the urine in 48 hours was 128 and 48 mg, respectively, with the immediate-release capsules, and 112 and 33 mg, respectively, with Norpace CR capsules. The differences in the urinary excretion of either constituent were not statistically significant.</p>
<p>Following multiple doses, steady-state plasma levels of between 2 and 4 mcg/ml were attained following either 150 mg every-6-hour dosing with immediate-release capsules or 300 mg every-12-hour dosing with Norpace CR capsules.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.6"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Effects of other drugs on disopyramide pharmacokinetics: In vitro metabolic studies indicated that disopyramide is metabolized by cytochrome P450 3A4 and that inhibitors of this enzyme may result in elevation of plasma levels of disopyramide. Although specific drug interaction studies have not been done, cases of life-threatening interactions have been reported for disopyramide when given with clarithromycin and erythromycin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Norpace and Norpace CR are indicated for the treatment of documented <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, such as <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">sustained ventricular tachycardia</span>, that, in the judgment of the physician, are life-threatening. Because of the <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmic effects</span> of Norpace and Norpace CR, their use with lesser <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided.</p>
<p>Initiation of Norpace or Norpace CR treatment, as with other antiarrhythmic agents used to treat life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, should be carried out in the hospital. Norpace CR should not be used initially if rapid establishment of disopyramide plasma levels is desired.</p>
<p>Antiarrhythmic drugs have not been shown to enhance survival in patients with <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Norpace and Norpace CR are contraindicated in the presence of <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, preexisting second- or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> (if no pacemaker is present), congenital Q-T prolongation, or known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warn"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Warning">
<a name="section-5.1"></a><p></p>
<h2>Mortality</h2>
<p class="First"><span class="Bold">In the National Heart, Lung and Blood Institute's <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Arrhythmia</span> Suppression Trial (CAST), a long-term, multi-center, randomized, double-blind study in patients with asymptomatic non-life-threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> who had had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> more than 6 days but less than 2 years previously, an excessive mortality or non-fatal <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3.0%). The average duration of treatment with encainide or flecainide in this study was 10 months.</span></p>
<p class="Bold">The applicability of the CAST results to other populations (e.g., those without recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>) is uncertain. Considering the known proarrhythmic properties of Norpace or Norpace CR and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, the use of Norpace or Norpace CR as well as other antiarrhythmic agents should be reserved for patients with life-threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>Negative Inotropic Properties</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>/<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h3>
<p class="First"><span class="Bold">Norpace or Norpace CR may cause or worsen <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or produce severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> as a consequence of its negative inotropic properties. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> has been observed primarily in patients with primary <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> or inadequately compensated <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Norpace or Norpace CR should not be used in patients with uncompensated or marginally compensated <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> unless the <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is secondary to <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>. Patients with a history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> may be treated with Norpace or Norpace CR, but careful attention must be given to the maintenance of cardiac function, including optimal digitalization. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> worsens, Norpace or Norpace CR should be discontinued and, if necessary, restarted at a lower dosage only after adequate cardiac compensation has been established.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.2"></a><p></p>
<h3>QRS Widening</h3>
<p class="First"><span class="Bold">Although it is unusual, significant widening (greater than 25%) of the <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span> may occur during Norpace or Norpace CR administration; in such cases Norpace or Norpace CR should be discontinued.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.3"></a><p></p>
<h3>Q-T Prolongation</h3>
<p class="First"><span class="Bold">As with other Type 1 antiarrhythmic drugs, prolongation of the Q-T interval (corrected) and worsening of the <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, may occur. Patients who have evidenced prolongation of the Q-T interval in response to quinidine may be at particular risk. As with other Type 1A antiarrhythmics, disopyramide phosphate has been associated with <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>.</span></p>
<p class="Bold">If a Q-T prolongation of greater than 25% is observed and if ectopy continues, the patient should be monitored closely, and consideration given to discontinuing Norpace or Norpace CR.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h3>
<p class="First">The physician should be alert to this possibility, especially in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, chronic <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span>, hepatic, renal or other diseases, or drugs (e.g., beta-adrenoceptor blockers, alcohol) which could compromise preservation of the normal glucoregulatory mechanisms in the absence of food. In these patients the blood-glucose levels should be carefully followed.
                                            <span class="Bold">In rare instances significant lowering of blood-glucose values has been reported during Norpace administration.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.5"></a><p></p>
<h3>Concomitant Antiarrhythmic Therapy</h3>
<p class="First">This should be considered particularly in patients with any degree of cardiac decompensation or those with a prior history thereof. Patients receiving more than one antiarrhythmic drug must be carefully monitored.
                                            <span class="Bold">The concomitant use of Norpace or Norpace CR with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> who are demonstrably unresponsive to single-agent antiarrhythmic therapy. Such use may produce serious negative inotropic effects, or may excessively prolong conduction.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Heart Block</span></h3>
<p class="First">If the block persists despite reduction of dosage, continuation of the drug must depend upon weighing the benefit being obtained against the risk of higher degrees of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. Development of second- or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> or unifascicular, bifascicular, or trifascicular block requires discontinuation of Norpace or Norpace CR therapy, unless the ventricular rate is adequately controlled by a temporary or implanted ventricular pacemaker.
                                            <span class="Bold">If first-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> develops in a patient receiving Norpace or Norpace CR, the dosage should be reduced.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AntiCh-Act"></a><a name="section-5.1.7"></a><p></p>
<h3>Anticholinergic Activity</h3>
<p class="First">these consist of the topical application of potent miotics (e.g., pilocarpine) for patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, and catheter drainage or operative relief for patients with <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span> may occur in patients of either sex as a consequence of Norpace or Norpace CR administration, but males with <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hypertrophy</span> are at particular risk. In patients with a family history of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, intraocular pressure should be measured before initiating Norpace or Norpace CR therapy. Disopyramide phosphate should be used with special care in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> since its anticholinergic properties could precipitate a myasthenic crisis in such patients.
                                            <span class="Bold">Because of its anticholinergic activity, disopyramide phosphate should not be used in patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, or <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> unless adequate overriding measures are taken;</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3>Atrial <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachyarrhythmias</span></h3>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> or <span class="product-label-link" type="condition" conceptid="4226399" conceptname="Fibrillation">fibrillation</span> should be digitalized prior to Norpace or Norpace CR administration to ensure that drug-induced enhancement of AV conduction does not result in an increase of ventricular rate beyond physiologically acceptable limits.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<h3>Conduction Abnormalities</h3>
<p class="First">Care should be taken when prescribing Norpace or Norpace CR for patients with <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span> (<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>-<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> syndrome), Wolff-Parkinson-White syndrome (WPW), or <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>. The effect of disopyramide phosphate in these conditions is uncertain at present.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></h3>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or other <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> may develop significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in response to the usual dosage of disopyramide phosphate, probably due to cardiodepressant mechanisms. Therefore, a loading dose of Norpace should not be given to such patients, and initial dosage and subsequent dosage adjustments should be made under close supervision (see ).
                                            <span class="Italics"><a href="#Dos-Adm">Dosage and Administration</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Ren-Imp"></a><a name="section-6.1.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h3>
<p class="First">More than 50% of disopyramide is excreted in the urine unchanged. Therefore Norpace dosage should be reduced in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (see ). The electrocardiogram should be carefully monitored for prolongation of PR interval, evidence of QRS widening, or other signs of overdosage (see ).
                                            <span class="Italics"><a href="#Dos-Adm">Dosage and Administration</a></span><span class="Italics"><a href="#Ovr-dos">Overdosage</a></span></p>
<p>Norpace CR is not recommended for patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (creatinine clearance 40 ml/min or less).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span> also causes an increase in the plasma half-life of disopyramide. Dosage should be reduced for patients with such impairment. The electrocardiogram should be carefully monitored for signs of overdosage (see ).
                                            <span class="Italics"><a href="#Ovr-dos">Overdosage</a></span></p>
<p>Patients with cardiac dysfunction have a higher potential for <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>; this should be considered when administering Norpace or Norpace CR.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6"></a><p></p>
<h3>Potassium Imbalance</h3>
<p class="First">Antiarrhythmic drugs may be ineffective in patients with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and their toxic effects may be enhanced in patients with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Therefore, potassium abnormalities should be corrected before starting Norpace or Norpace CR therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur. Monitoring of disopyramide plasma levels is recommended in such concurrent use to avoid ineffective therapy. Other antiarrhythmic drugs (e.g., quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace. Excessive widening of the <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span> and/or prolongation of the Q-T interval may occur in these situations (see ). In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either propranolol or diazepam. Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels. Norpace does not increase serum digoxin levels.
                                    <span class="Italics"><a href="#Warn">Warnings</a></span></p>
<p>Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.</p>
<p>Although potent inhibitors of cytochrome P450 3A4 (e.g., ketoconazole) have not been studied clinically, in vitro studies have shown that erythromycin and oleandomycin inhibit the metabolism of disopyramide. Cases of life-threatening interactions have been reported for disopyramide when given with clarithromycin and erythromycin indicating that coadministration of disopyramide with inhibitors of cytochrome 3A4 could result in potentially fatal interaction.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Eighteen months of Norpace administration to rats, at oral doses up to 400 mg/kg/day (about 30 times the usual daily human dose of 600 mg/day, assuming a patient weight of at least 50 kg), revealed no evidence of carcinogenic potential. An evaluation of mutagenic potential by Ames test was negative. Norpace, at doses up to 250 mg/kg/day, did not adversely affect fertility of rats.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-6.4.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Norpace was associated with decreased numbers of implantation sites and decreased growth and survival of pups when administered to pregnant rats at 250 mg/kg/day (20 or more times the usual daily human dose of 12 mg/kg, assuming a patient weight of at least 50 kg), a level at which <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption of dams were also reduced. Increased resorption rates were reported in rabbits at 60 mg/kg/day (5 or more times the usual daily human dose). Effects on implantation, pup growth, and survival were not evaluated in rabbits. There are no adequate and well-controlled studies in pregnant women. Norpace or Norpace CR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-6.4.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Disopyramide has been found in human fetal blood.
                                            <span class="Bold">Norpace has been reported to stimulate contractions of the pregnant uterus.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-6.5"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">It is not known whether the use of Norpace or Norpace CR during labor or delivery has immediate or delayed adverse effects on the fetus, or whether it prolongs the duration of labor or increases the need for forceps delivery or other obstetric intervention.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Studies in rats have shown that the concentration of disopyramide and its metabolites is between one and three times greater in milk than it is in plasma. Following oral administration, disopyramide has been detected in human milk at a concentration not exceeding that in plasma. Because of the potential for serious adverse reactions in nursing infants from Norpace or Norpace CR, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established (see ).
                                    <span class="Italics"><a href="#Dos-Adm">Dosage and Administration</a></span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Norpace/Norpace CR did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>Because of its anticholinergic activity, disopyramide phosphate should not be used in patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, or <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hypertrophy</span> (medical conditions commonly associated with the elderly) unless adequate overriding measures are taken (see ). In the event of increased anticholinergic side effects, plasma levels of disopyramide should be monitored and the dose of the drug adjusted accordingly. A reduction of the dose by one third, from the recommended 600 mg/day to 400 mg/day, would be reasonable, without changing the dosing interval.
                                    <span class="Italics"><a href="#AntiCh-Act">Warnings: Anticholinergic Activity</a></span></p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see and ).
                                    <span class="Italics"><a href="#Ren-Imp">Precautions: <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></span><span class="Italics"><a href="#Dos-Adm">Dosage and Administration</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Adv-React"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The adverse reactions which were reported in Norpace clinical trials encompass observations in 1,500 patients, including 90 patients studied for at least 4 years. The most serious adverse reactions are <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. The most common adverse reactions, which are dose dependent, are associated with the anticholinergic properties of the drug. These may be transitory, but may be persistent or can be severe. <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span> is the most serious anticholinergic effect.</p>
<p>The following reactions were reported in 10% to 40% of patients:</p>
<p>Anticholinergic: <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (32%), <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitancy</span> (14%), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (11%)</p>
<p>The following reactions were reported in 3% to 9% of patients:</p>
<p>Anticholinergic: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4171214" conceptname="Nasal mucosa dry">dry nose</span>/eyes/throat</p>
<p>Genitourinary: <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span> and urgency</p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/<span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>/gas</p>
<p>General: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, general <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>/<span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">aches</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pains</span></p>
<p>The following reactions were reported in 1% to 3% of patients:</p>
<p>Genitourinary: <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span></p>
<p>Cardiovascular: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with or without <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, increased <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (see ), cardiac conduction disturbances (see ), <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>/<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>
                            <span class="Italics"><a href="#Warn">Warnings</a></span><span class="Italics"><a href="#Warn">Warnings</a></span></p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p>Dermatologic: generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>/dermatoses, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></p>
<p>Central nervous system: <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span></p>
<p>Other: <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, elevated <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>/triglycerides</p>
<p>The following reactions were reported in less than 1%:</p>
<p><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>/<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, elevated liver enzymes, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, elevated BUN, elevated creatinine, <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">decreased hemoglobin</span>/hematocrit</p>
<p><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> has been reported in association with Norpace administration (see ).
                            <span class="Italics"><a href="#Warn">Warnings</a></span></p>
<p>Infrequent occurrences of reversible <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and respiratory difficulty have been reported in association with disopyramide therapy, as have rare instances of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, reversible <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>. Some cases of LE (<span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>) symptoms have been reported; most cases occurred in patients who had been switched to disopyramide from procainamide following the development of LE symptoms. Rarely, acute <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> has been reported following Norpace therapy, with prompt return to normal mental status when therapy was stopped. The physician should be aware of these possible reactions and should discontinue Norpace or Norpace CR therapy promptly if they occur.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Ovr-dos"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Symptoms</h2>
<p class="First">Deliberate or accidental overdosage of oral disopyramide may be followed by <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, and loss of spontaneous respiration. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> has occurred following overdosage.</p>
<p>Toxic plasma levels of disopyramide produce excessive widening of the <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span> and Q-T interval, worsening of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, varying kinds and degrees of conduction disturbance, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and finally <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>. Obvious anticholinergic effects are also observed.</p>
<p>The approximate oral LD of disopyramide phosphate is 580 and 700 mg/kg for rats and mice, respectively.
                                    <span class="Sub">50</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">Experience indicates that prompt and vigorous treatment of overdosage is necessary, even in the absence of symptoms. Such treatment may be life-saving. No specific antidote for disopyramide phosphate has been identified. Treatment should be symptomatic and may include induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or gastric lavage, administration of a cathartic followed by activated charcoal by mouth or stomach tube, intravenous administration of isoproterenol and dopamine, insertion of an intra-aortic balloon for counterpulsation, and mechanically assisted ventilation. Hemodialysis or, preferably, hemoperfusion with charcoal may be employed to lower serum concentration of the drug.</p>
<p>The electrocardiogram should be monitored, and supportive therapy with cardiac glycosides and diuretics should be given as required.</p>
<p>If progressive <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> should develop, endocardial pacing should be implemented. In case of any <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, measures to increase the glomerular filtration rate may reduce the toxicity (disopyramide is excreted primarily by the kidney).</p>
<p>The anticholinergic effects can be reversed with neostigmine at the discretion of the physician.</p>
<p>Altering the urinary pH in humans does not affect the plasma half-life or the amount of disopyramide excreted in the urine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Dos-Adm"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dosage of Norpace or Norpace CR must be individualized for each patient on the basis of response and tolerance. The usual adult dosage of Norpace or Norpace CR is 400 to 800 mg per day given in divided doses. The recommended dosage for most adults is 600 mg/day given in divided doses (either 150 mg every 6 hours for immediate-release Norpace or 300 mg every 12 hours for Norpace CR). For patients whose body weight is less than 110 pounds (50 kg), the recommended dosage is 400 mg/day given in divided doses (either 100 mg every 6 hours for immediate-release Norpace or 200 mg every 12 hours for Norpace CR). In the event of increased anticholinergic side effects, plasma levels of disopyramide should be monitored and the dose of the drug adjusted accordingly. A reduction of the dose by one third, from the recommended 600 mg/day to 400 mg/day, would be reasonable, without changing the dosing interval.</p>
<p>Subsequent dosage adjustments should be made gradually, with close monitoring for the possible development of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (see ).
                            <span class="Bold">For patients with <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> or possible cardiac decompensation, a loading dose, as discussed below, should not be given, and initial dosage should be limited to 100 mg of immediate-release Norpace every 6 to 8 hours.</span><span class="Italics"><a href="#Warn">Warnings</a></span></p>
<p>For patients with moderate <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (creatinine clearance greater than 40 ml/min) or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, the recommended dosage is 400 mg/day given in divided doses (either 100 mg every 6 hours for immediate-release Norpace or 200 mg every 12 hours for Norpace CR).</p>
<p>For patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (C 40 ml/min or less), the recommended dosage regimen of immediate-release Norpace is 100 mg at intervals shown in the table below, with or without an initial loading dose of 150 mg.
                            <span class="Sub">cr</span></p>
<table width="60%">
<caption><span>IMMEDIATE-RELEASE NORPACE DOSAGE INTERVAL FOR PATIENTS WITH <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">RENAL INSUFFICIENCY</span></span></caption>
<col align="left" valign="bottom" width="28%">
<col align="center" valign="bottom" width="24%">
<col align="center" valign="bottom" width="24%">
<col align="center" valign="bottom" width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="left">Creatinine clearance (ml/min)
                                        <br>
</td>
<td class="Botrule" align="center">40–30</td>
<td class="Botrule" align="center">30–15</td>
<td class="Botrule" align="center">less than 15</td>
</tr>
<tr class="Last">
<td align="left">Approximate maintenance-dosing interval</td>
<td align="center">q 8 hr</td>
<td align="center">q 12 hr</td>
<td align="center">q 24 hr</td>
</tr>
</tbody>
</table>
<p>The above dosing schedules are for Norpace immediate-release capsules; Norpace CR is not recommended for patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<p>For patients in whom rapid control of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> is essential, an initial loading dose of 300 mg of immediate-release Norpace (200 mg for patients whose body weight is less than 110 pounds) is recommended, followed by the appropriate maintenance dosage. Therapeutic effects are usually attained 30 minutes to 3 hours after administration of a 300-mg loading dose. If there is no response or evidence of toxicity within 6 hours of the loading dose, 200 mg of immediate-release Norpace every 6 hours may be prescribed instead of the usual 150 mg. If there is no response to this dosage within 48 hours, either Norpace should then be discontinued or the physician should consider hospitalizing the patient for careful monitoring while subsequent immediate-release Norpace doses of 250 mg or 300 mg every 6 hours are given. A limited number of patients with severe refractory <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> have tolerated daily doses of Norpace up to 1600 mg per day (400 mg every 6 hours), resulting in disopyramide plasma levels up to 9 mcg/ml. If such treatment is warranted, it is essential that patients be hospitalized for close evaluation and continuous monitoring.</p>
<p>Norpace CR should not be used initially if rapid establishment of disopyramide plasma levels is desired.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Transferring to Norpace or Norpace CR</h2>
<p class="First">The following dosage schedule based on theoretical considerations rather than experimental data is suggested for transferring patients with normal renal function from either quinidine sulfate or procainamide therapy (Type 1 antiarrhythmic agents) to Norpace or Norpace CR therapy:</p>
<p>Norpace or Norpace CR should be started using the regular maintenance schedule 6 to 12 hours after the last dose of quinidine sulfate or 3 to 6 hours after the last dose of procainamide.
                                    <span class="Bold">without a loading dose</span></p>
<p>In patients in whom withdrawal of quinidine sulfate or procainamide is likely to produce life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, the physician should consider hospitalization of the patient. When transferring a patient from immediate-release Norpace to Norpace CR, the maintenance schedule of Norpace CR may be started 6 hours after the last dose of immediate-release Norpace.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Pediatric Dosage</h2>
<p class="First">Controlled clinical studies have not been conducted in pediatric patients; however, the following suggested dosage table is based on published clinical experience.</p>
<p>Total daily dosage should be divided and equal doses administered orally every 6 hours or at intervals according to individual patient needs. Disopyramide plasma levels and therapeutic response must be monitored closely. Patients should be hospitalized during the initial treatment period, and dose titration should start at the lower end of the ranges provided below.</p>
<table width="50%">
<caption><span>SUGGESTED TOTAL DAILY DOSAGE
                                        <a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="60%">
<thead><tr class="First Last">
<th align="center">Age (years)
                                                <br>
</th>
<th align="center">Disopyramide (mg/kg body weight/day)
                                                <br>
</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Dosage is expressed in milligrams of disopyramide base. Since Norpace (disopyramide phosphate) 100-mg capsules contain 100 mg of disopyramide base, the pharmacist can readily prepare a 1-mg/mL to 10-mg/mL liquid suspension by adding the entire contents of Norpace capsules to cherry syrup. (Prepare cherry syrup as follows: cherry juice, 475 ml; sucrose 800 g; alcohol, 20 ml; purified water, a sufficient quantity to make 1000 ml.) The resulting suspension, when refrigerated, is stable for one month and should be thoroughly shaken before the measurement of each dose. The suspension should be dispensed in an amber glass bottle with a child-resistant closure.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center">Under 1</td>
<td align="center">10 to 30</td>
</tr>
<tr>
<td align="center">1 to 4</td>
<td align="center">10 to 20</td>
</tr>
<tr>
<td align="center">4 to 12</td>
<td align="center">10 to 15</td>
</tr>
<tr class="Last">
<td align="center">12 to 18</td>
<td align="center">6 to 15</td>
</tr>
</tbody>
</table>
<p>Norpace CR capsules should not be used to prepare the above suspension.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NDC:68151-0527-3 in a PACKAGE of 1 CAPSULE, GELATIN COATEDS</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<h2></h2>
<p class="First">Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F). [See USP Controlled Room Temperature.]</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p><img alt="G.D. Searle LLC logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f5e0c230-db38-4476-8357-9a227ccff1bc&amp;name=norpace-02.jpg"></p>
<p>LAB-0066-2.0</p>
<p>Revised September 2006</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>Disopyramide Phosphate</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f5e0c230-db38-4476-8357-9a227ccff1bc&amp;name=68151-0527.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NORPACE 		
					</strong><br><span class="contentTableReg">disopyramide phosphate capsule, gelatin coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68151-0527(NDC:0025-2742)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>disopyramide phosphate</strong> (disopyramide) </td>
<td class="formItem">disopyramide</td>
<td class="formItem">150 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ETHYLCELLULOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN, GREEN (Light Green) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SEARLE;2742;NORPACE;CR;150;MG</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68151-0527-3</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018655</td>
<td class="formItem">07/20/1982</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Carilion Materials Management
							(079239644)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Carilion Materials Management (079239644)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Carilion Materials Management</td>
<td class="formItem"></td>
<td class="formItem">079239644</td>
<td class="formItem">REPACK(68151-0527)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ab01df3a-64fa-41c8-a5f3-e71003d5b298</div>
<div>Set id: f5e0c230-db38-4476-8357-9a227ccff1bc</div>
<div>Version: 2</div>
<div>Effective Time: 20100224</div>
</div>
</div> <div class="DistributorName">Carilion Materials Management</div></p>
</body></html>
